# Tamarind Bio

> Tamarind Bio is a San Francisco software company building cloud infrastructure that lets bench scientists run 250+ AI and physics-based models for drug discovery - tools like AlphaFold, RFdiffusion, ProteinMPNN and GROMACS - through a no-code web interface and API, without managing GPUs, data pipelines or DevOps. Founded in 2023 by Stanford computer scientist Deniz Kavi and Sherry Liu, the company serves over 10,000 scientists, including 8 of the top 20 pharmaceutical companies, and raised a $13.6M Series A in February 2026.

- **Founded:** 2023
- **Headquarters:** San Francisco, California, United States
- **Founders:** Deniz Kavi (Co-founder & CEO), Sherry Liu (Co-founder)
- **Team size:** ~13 employees
- **Products:** AI Inference Platform, Protein Design, Peptide Discovery, Enzyme Engineering, Small Molecule Design
- **Notable:** Raised $13.6M Series A led by Dimension Capital (February 2026), Grew to over 10,000 scientists and ~100 biotech organizations in roughly two years, Adopted by 8 of the top 20 pharmaceutical companies

## Products & services

- **AI Inference Platform** — A cloud platform that runs 250+ AI and physics-based models for molecular design through a no-code web interface and programmatic API, handling GPU orchestration, parallelization and high-performance compute.
- **Protein Design** — Antibody, nanobody and mini-protein design and optimization using models like RFdiffusion and ProteinMPNN.
- **Peptide Discovery** — De novo binder design and sequence optimization for peptide therapeutics.
- **Enzyme Engineering** — Sequence and structure optimization for enzyme design.
- **Small Molecule Design** — Computational tools for small molecule generation and property prediction.
- **Molecular Simulation** — Molecular dynamics and physics-based simulation via tools such as GROMACS.
- **Enterprise & Custom Models** — Proprietary enterprise model hosting, model training, and multi-stage scalable pipelines with SOC 2 compliant security and full customer data ownership.

## Achievements

- Raised $13.6M Series A led by Dimension Capital (February 2026)
- Grew to over 10,000 scientists and ~100 biotech organizations in roughly two years
- Adopted by 8 of the top 20 pharmaceutical companies
- Expanded model library to 250+ AI and physics-based models
- Reported 700% year-over-year growth
- Reached 600+ users in the first month after launch
- Y Combinator Winter 2024 batch

## Latest updates

- **2026-04** — Partnered with A-Alpha Bio to connect computational antibody design with high-throughput experimental validation via AlphaSeq.
- **2026-02** — Raised $13.6M Series A led by Dimension Capital with participation from Y Combinator.
- **2026-02** — Model library expanded past 250 models spanning antibodies, peptides, small molecules, enzymes and radiopharmaceuticals.

## Links

- Website: https://www.tamarind.bio
- LinkedIn: https://www.linkedin.com/company/tamarind-bio
- Twitter/X: https://x.com/tamarindbio

---

Profile page: https://yespress.io/tamarind-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-11